On August 27, 2021 BeiGene (NASDAQ:BGNE) and Immix Biopharma reported a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a combination of IMX-110 and tislelizumab for the treatment of various solid tumors (Press release, Immix Biopharma, AUG 27, 2021, View Source [SID1234587963]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, ImmixBio will evaluate the combination of IMX-110 with tislelizumab in a Phase 1/2a trial in patients with advanced solid tumors.

"We have high hopes that IMX-110 in combination with tislelizumab could expand the population of cancer patients experiencing extended remissions," ImmixBio CEO Ilya Rachman said.